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ABSTRACT
Background and the purpose of the study: Domperidone (DOM) is a dopamine- receptor (D2) 
antagonist, which is widely used in the treatment of motion-sickness. The pharmacokinetic 
parameters make DOM a suitable candidate for transdermal delivery. The purpose of the present 
investigation was to develop transdermal delivery systems for DOM and to evaluate their 
physicochemical characteristics, in vitro release an ex vivo permeation through rat abdominal 
skin and their mechanical properties.
Methods: Bilayered matrix type transdermal drug delivery systems (TDDS) of DOM were 
prepared by film casting technique using hydroxypropyl methyl cellulose as primary  and 
Eudragit RL 100 as secondary layers. Brij-35 was incorporated as a solubilizer, d-limonene 
and propylene glycol were employed as permeation enhancer and plasticizer respectively. The 
prepared TDDS were extensively evaluated for in vitro release, moisture absorption, moisture 
content, water vapor transmission, ex vivo permeation through rat abdominal skin, mechanical 
properties and stability studies. The physicochemical interaction between DOM and polymers 
were investigated by Differential Scanning Calorimetry (DSC) and Fourier Transform Infrared 
Spectroscopy (FTIR).
Results:  All  the  formulations  exhibited  satisfactory  physicochemical  and  mechanical 
characteristics. The optimized formulation F6 showed maximum cumulative percentage of drug 
release (90.7%), permeation (6806.64 µg) in 24 hrs, flux (86.02 µg /hr/cm2) and permeation 
coefficient of 0.86x10-2 cm/hr. Values of tensile strength (4.34 kg/mm2) and elastic modulus 
(5.89 kg/cm2) revealed that formulation F6 was strong but not brittle. DSC and FTIR studies 
showed no evidence of interaction between the drug and polymers. A shelf life of 2 years is 
predicted for the TDDS.   
Conclusions: Domperidone bilayered matrix type transdermal therapeutic systems could be 
prepared with the required flux and suitable mechanical properties.
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INTRODUCTION 
The transdermal route of administration has been 
recognized as one of the potential routes for local 
and  systemic  delivery  of  drugs. This  route  offers 
many advantages over the oral dosage form, such as 
improving patient compliance in long-term therapy, 
bypassing  first-pass  metabolism,  sustaining  drug 
delivery, maintaining a constant and prolonged drug 
level in plasma, minimizing inter- and intra patient 
variability,  and  making  it  possible  to  interrupt  or 
terminate treatment when necessary (1). However, 
the highly organized structure of the stratum corneum 
forms an effective barrier to drug permeation, which 
must be modified if poorly penetrating drugs are to 
be administered. The use of chemical penetration 
enhancers  significantly  increases  the  number  of 
drug  molecules  suitable  for  transdermal  delivery 
(2,  3).  In  addition,  the  transdermal  patch  dosage 
form is user-friendly, convenient and painless, and 
generally  leads  to  improved  patient  compliance. 
Intensive research has shown that transdermal route 
is a potential mode of delivery for lipophilic drugs in 
systemic circulation (4). 
Domperidone is a dopamine- receptor (D2) antagonist, 
widely  used  in  the  treatment  of  motion-sickness. 
In  humans,  peak  plasma  levels  of  domperidone 
occur within 10 to 30 min following intra-muscular 
injection and 30 min after oral (fasted) administration. 
It has been reported that it is rapidly absorbed after 
oral  administration,  but  undergoes  extensive  first 
pass  metabolism;  leading  to  poor  bioavailability 
of  15%  (5).  From  both,  physicochemical  (low 
molecular weight 425.9g/mol, low dose 10 mg) and 
pharmacokinetic  (absolute  bioavailability  about 
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0 % d-limonene served as control and PEG 400 was 
used to solubilize DOM. The receiver compartment 
contained 25 ml of 40 % v/v PEG 400 in PBS of pH 
7.4 and the contents were stirred at 500 rpm using 
magnetic stirrer. The entire assembly was kept at 
37 ± 0.5 oC. Samples of 1 ml were collected at preset 
time points upto 24 hrs and replenished with fresh 
buffer. The samples were filtered through 0.45 μ 
syringe filter (Sartorius AG, Goettingen, Germany) 
and  drug  content  in  the  samples  was  determined 
by high performance liquid chromatography (HPLC) 
(16). 
HPLC methodology for DOM
HPLC determination of DOM was performed using 
Shimadzu LC 20AT solvent delivery pump equipped 
with a 20 µl loop, rheodyne sample injector and UV-
visible  detector.    Samples  were  chromatographed 
on a reverse phase C18 column (250 × 4.25 mm, 5 
μm particle Phenomenex, Gemini column). Elution 
was conducted with a mobile phase of acetonitrile: wa-
ter at ratio of 31:69 v/v containing 0.25% v/v or of 
triethyl-amine of pH 2.5 at a flow rate of 1 ml /min. 
A calibration curve was plotted for DOM in the con-
centration range of 0.5-10 µg ml-1. A good linear re-
lationship was observed between the concentration 
of DOM and the peak area of DOM (r2 = 0.999). 
The required studies were carried out to estimate 
the precision and accuracy of the HPLC method.
Development of bilayered transdermal systems  
Bilayered  matrix  type  transdermal  patches  were 
prepared using solvent casting technique (17) with 
HPMC E15 as primary polymeric layer, Eudragit 
RLPO  as  secondary  polymeric  layer,  Brij-35  (a 
non-ionic surfactant) as a solubilizer and propylene 
glycol  as  plasticizer.  Primary  polymer  was  added 
to 20 ml of the solvent mixture (dichloromethane 
and methanol, 1:1) and allowed to stand for 6 hrs 
to swell. Brij-35 and DOM were dissolved in 5 ml of 
solvent mixture and added to the polymeric solution. 
Measured quantity of d-limonene (12% v/v) was added 
as penetration enhancer. This was set aside for 2 hrs 
to  remove  entrapped  air,  then  transferred  to  a  petri 
plate, and dried at room temperature. The secondary 
polymeric  solution  was  prepared  by  dissolving  300 
mg of Eudragit RLPO and 60 µl of propylene glycol 
in 15 ml of solvent mixture and poured on the primary 
polymer layer and allowed to dry at room temperature. 
The developed patches were removed carefully, cut to 
size (each having an area of 3.14 cm2), and stored in 
a desiccator. The composition of the patches is shown 
in table 1. Patches were subjected to weight, thickness 
variation and content uniformity. 
Evaluation of physicochemical properties
Six films from each series were weighed individually 
and the average weight was calculated. The thickness 
of the patch was measured at six different points of 
10-20 % and log P, 3.11) perspective, DOM was 
considered to be a suitable candidate for transdermal 
delivery.
In spite of several advantages offered by transdermal 
route, only a few drug molecules are administered 
transdermally  because  of  the  formidable  barrier 
nature of stratum corneum (6). Two major approaches 
to  increase  transdermal  permeation  rate  include 
physical techniques (iontophoresis, electroporation, 
sonophoresis, and microneedles) and use of chemical 
penetration enhancers such as solvents, surfactants, 
fatty  acids  and  terpenes  (7-10).  Terpenes  present 
in  naturally  occurring  volatile  oils  appear  to  be 
clinically  acceptable  enhancers  (11).  Moreover,  a 
wide variety of terpenes have been shown to increase 
the percutaneous absorption of a number of drugs 
(12). In the present study d- limonene was used as 
penetration enhancer, as reported earlier for some 
other drugs (13, 14). 
In the initial trials which were made with monolayer 
patches, drug diffusion from the monolayer patches 
was observed. In order to prevent the drug diffusing 
from the surface of the patch, bilayered transdermal 
patches were developed. The objective of present 
investigation  was  development  of  bilayered 
transdermal  therapeutic  systems  for  DOM  and  to 
evaluate  physicochemical,  mechanical  properties, 
in vitro release and ex vivo permeation through rat 
abdominal skin.
MATERIAL AND METHODS
  
Materials  
Domperidone,  Hydroxypropyl  methylcellulose 
(HPMC E15) and Eudragit RL 100 (ERL 100) were 
gift samples from Torrent pharmaceuticals (Baroda, 
India) and Dr. Reddy’s laboratories (Hyderabad, 
India) respectively. Transcutol and d-limonene were 
purchased from Gattefosse, (France) and Hi Media 
(Mumbai, India) respectively. All other chemicals 
were of analytical grade.
 
Preparation of rat abdominal skin  
Albino rats weighing 150-200 g were sacrificed using 
anesthetic ether. Heat separation technique was used 
to prepare the epidermis (15), which involved soaking 
the entire abdominal skin in water at 60 oC for 45 sec, 
followed by careful removal of the epidermis. The 
epidermis was washed with water and used for ex 
vivo permeability studies.
Effect of d-limonene on permeation of DOM
Effect  of  d-limonene  on  permeation  of  DOM 
through rat abdominal skin was studied using franz 
diffusion cell. DOM solution [5 mg in 4 ml of the 
phosphate buffered saline (PBS) of pH 5.6 containing 
polyethylene glycol (PEG 400)] was placed in the 
donor compartment containing different concentra-
tions of d-limonene (0, 4, 8, 12 and 16 % v/v). The 223
the  patch  using  digital  gauze  (Mitutoyo,  Japan). 
Patches from each series of formulations (n=3) of 
3.14 cm2 area were cut into pieces and weighed. The 
pieces were taken into a 100 ml volumetric flask, 
allowed to dissolve in 2 ml of dimethyl formamide 
and adjusted to 100 ml with 0.1N hydrochloric acid 
solution. The solution was filtered through 0.45 µm 
membrane filters and the drug content was analyzed 
using UV-visible spectrophotometer at 284 nm. 
Moisture absorption study  
The films were weighed accurately and placed in a 
desiccator containing 100 ml of saturated solution 
of aluminum chloride (79.5% RH). After 3 days, the 
films were taken out and weighed. The percentage 
of moisture uptake was calculated as the difference 
between the final and initial weight with respect to 
the initial weight (18).
Moisture content  
The patches were weighed and kept in a desiccator 
containing calcium chloride at 40 oC for 24 hrs. The 
final weight was noted when there was no further 
change in the weight of patch. The percentage of 
moisture  content  was  calculated  as  a  difference 
between initial and final weight with respect to the 
final weight (19).  
Water Vapor Transmission Rate (WVTR) Studies  
WVTR  studies  were  performed  according  to  the 
modified method described by Kusum et al. (18). 
Glass vials of equal diameter which were used as 
transmission cells were washed thoroughly and dried 
in oven. About 1 g of anhydrous calcium chloride was 
placed in the cells and the respective polymer film 
was fixed over the brim. The cells were accurately 
weighed and kept in a closed desiccator containing 
saturated solution of potassium chloride to maintain 
a relative humidity of 84%. The cells were taken out 
and weighed after 24 hrs. The amount of water vapor 
transmitted was determined using following formula:  
 
Water vapor transmission rate is expressed as the 
number of grams of moisture gained/hr/cm2. 
Measurement of mechanical properties
The  film’s  mechanical  properties  were  evaluated 
using a microprocessor-based advanced force gauge 
(Ultra Test, Mecmesin, UK) equipped with a 25 kg 
load cell. Film strips with dimensions of 60 × 10 
mm and free from physical imperfections were held 
between two clamps positioned at a distance of 3 
cm. During measurement, the top clamp pulled the 
strips at a rate of 2 mm/s until the film broke. The 
force required to break a film and elongation at a 
break were measured using dataplot software. The 
mechanical properties were calculated according to 
the following formulae (20). 
where, TS, E/B and EM represents tensile strength, 
elongation at break and elastic modulus respectively.
In vitro drug release studies  
Franz diffusion cell with a surface area of 3.46 cm2 
WVTR =
Final weight - Initial weight  
Time × Area
(1)
Component F1 F2 F3 F4 F5 F6 F7 F8 F9
Primary Layer
Domperidone (mg) 250 250 250 250 250 250 250 250 250
HPMC E15 (mg) 2000 2000 2000 2500 2500 2500 3000 3000 3000
Brij-35 (µL) 60 120 180 60 120 180 60 120 180
d-limonene (µL) 240 240 240 300 300 300 360 360 360
Propylene glycol (µL) 300 300 300 375 375 375 450 450 450
Secondary Layer
Eudragit RLPO (mg) 300 300 300 300 300 300 300 300 300
Propylene glycol (µL) 60 60 60 60 60 60 60 60 60
Table 1. Composition of Domperidone bilayered transdermal patches.
TS (Kg -2) =
Force at break (Kg) 
Initial cross sectional area of the sample (mm2)
(2)
(3)
E
B
( % mm -2) =
Increase in length (mm)
Original length (mm) × Cross sectional area (mm2)
× 100
EM (Kg mm -2) =
Force at correspovding strain (Kg) 
cross sectional area (mm2) ×
1
correspovding strain
(4)
Strain =
Tensile strength
Elastic modulus
(5)
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was used for in vitro release studies (21, 22). The 
transdermal patch was kept in the donor compartment 
and it was separated from the receptor compartment by 
dialysis membrane (Hi media M.W. cut off 5000). 
The donor and receptor compartment held together 
using clamp. The receiver compartment contained 
25 ml of PBS of pH 5.6 containing 20% v/v of 
PEG-400, stirred at 500 rpm and temperature was 
maintained at 37 ± 0.5  oC. Samples of 1 ml were 
withdrawn at pre-determined time intervals and rep-
lenished with an equal volume of fresh medium. The 
drug content in the samples was determined by UV/
visible  spectrophotometer  at  284  nm.  Cumulative 
percentage of the drug released were calculated and 
plotted against time (Figure 1). 
Ex vivo permeation studies  
Franz diffusion cell was used for ex vivo perme-
ation studies and the skin was mounted between the 
two compartments of the diffusion cell with stratum 
corneum facing the donor compartment. The stra-
tum corneum side of the skin was kept in intimate 
contact with the release surface of the TDDS under 
test. A dialysis membrane (Hi Media, M.W. cutoff 
5000) was placed over the patch, in order to secure 
the it tightly in the way that will not get dislodged 
from the skin. The receiver phase contained 12 ml 
PBS of pH 7.4 containing 20% v/v PEG 400 which 
was stirred at 500 rpm on a magnetic stirrer and the 
whole assembly was kept at 37 ± 0.5 oC. Samples of 
1 ml were withdrawn at pre-determined time inter-
vals upto 24 hrs, the volume was replenished with 
an equal volume of fresh medium and analyzed by 
HPLC. Cumulative amounts of drug permeated in 
µg/cm2 were plotted against time and drug flux ( µg/
cm2/hr) at steady state was calculated by dividing the 
slope of the linear portion of the curve by the area 
of the exposed skin surface (3.14 cm2) (22) and the 
permeability coefficient was deduced by dividing 
the flux by initial drug load. The target flux was 
calculated using the following equation (20). 
A,  represents  the  surface  area  of  the  transdermal 
patch (i.e. 3.14 cm2 ); BW, the standard human body 
weight of  60 kg; Css, the  domperidone concentration 
at the therapeutic level (11.35 µg/l) (23) and the Clt , the 
total body clearance (7-10 ml/min/kg); the calculated 
target flux value for DOM was  88.28 µg/cm2/hr.
Drug -polymer interaction study 
In order to determine a possible interaction between 
DOM and the polymeric materials of the patches, 
infrared (IR) spectroscopy and differential scanning 
calorimetry (DSC) studies were carried out on pure 
substances  and  their  physical  mixtures.  The  IR 
spectra were recorded using an IR-Spectrophotometer 
(PerkinElmer FT-IR, PerkinElmer, Waltham, MA) 
utilizing the KBr pellet method. DSC studies were 
conducted using a Differential Scanning Calorimeter 
(Mettler-Toledo,  Viroflay,  France).  The  samples 
were  scanned  at  10  °C/min  over  the  temperature 
range of 120 – 300 °C.
Stability studies  
The stability studies were conducted according to 
the  International  Conference  on  Harmonization 
(ICH) guidelines (24). The optimized formulation 
F6 was wrapped in an aluminum foil and placed in 
stability chamber (Labtop, India) at a temperature of 
J Target =
Css Clt BW
A
S.No Formulation Code weighta (mg) Thicknessa (µm) Drug contentb (%) wVT b (g/ cm2)×10-3
1 F1 150.0 ±  7.77 197.5 ± 3.53 100.8 ± 0.17 3.81 ± 0.05
2 F2 156.5 ±  6.36 196.6 ± 7.07 99.90 ± 0.11 5.27 ± 0.02
3 F3 153.5 ± 3.53 186.5 ± 4.94 101.5 ± 0.16 5.31 ± 0.08
4 F4 155.0 ±  5.65 207.0 ± 10.6 100.3 ± 0.11 5.52 ± 0.02
5 F5 150.8 ± 2.82 203.5 ±11.2 101.8 ± 0.26 5.11 ± 0.06
6 F6 157.5 ± 3.53 196.5 ± 4.94 99.30 ± 0.14 3.42 ± 0.09
7 F7 152.5 ± 2.12 202.0 ± 4.24 101.1 ± 0.21 3.87 ± 0.06
8 F8 153.5 ± 2.12 207.5 ± 8.48 98.80 ± 0.14 4.40 ±  0.06
9 F9 158.5 ± 7.07 195.0 ± 7.77 98.51 ± 0.16 6.81 ± 0.07
Table 2. Weight, Thickness, Drug content and Water Vapor Transmission Values of DOM transdermal patches.
aResults are mean ± SD (n= 6)  bResults are mean ± SD (n= 3)
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Figure 1: Effect of d-limonene concentration on cumulative permeation of DOM,  
Mean ± S.D (n = 3) 
Figure  1.  Effect  of  d-limonene  concentration  on  cumulative 
permeation of DOM, Mean ± S.D (n = 3).
(6)
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40 ± 0.5 oC and 75 ± 5% RH for 6 months. Samples 
were withdrawn at intervals of 1, 2, 3 and 6 months 
and analyzed for drug content and in vitro release.
RESULTS AND DISCUSSION 
Effect of d-limonene on permeation of DOM
The effect of concentration of d-limonene on cumulative 
permeation of DOM through rat skin is shown in figure 
1. Solution containing 12 and 16 % v/v of d-limonene 
showed similar flux values (125.9 ± 2.88 and 126.1 ± 2.38 
μg/cm2/hr) and permeability coefficients (25.1 ± 0.12 
and 25.2 ± 0.17 cm hr-1×10-2). The flux values which 
were obtained with 8 and 12 % v/v of d-limonene 
were  significantly  different  (p  <  0.05)  to  lowest 
values and were obtained with 4 and 8 % d-limonene 
(42.4 ± 1.47 and 62.7 ± 1.47 μg/cm2/hr) and control 
(10.8 ± 1.06 μg/cm2/hr). The permeability coefficients 
obtained with 12 and 16 % d-limonene were 12.4 and 
12.5 times higher than that observed with control. The 
permeation of DOM was not affected by increasing 
d-limonene concentration from 12 to 16 % v/v; hence 
in the preparation of patches, d-limonene was used at a 
concentration of 12 % v/v.
Weight, thickness variation and drug content  
The physicochemical properties (weight, thickness 
variation, drug content and water vapor transmission) 
of the transdermal patches are shown in table 2. The 
weight range of the patches were from 150.0 ± 7.77 
to 158.5 ± 7.07 mg and the thickness ranges were 
186.5 ± 4.94 to 207.5 ± 8.48μm. The results showed 
that the patches were uniform, as it was evidenced 
by RSD value, which were less than 6. The drug 
content ranged from 98.5 ± 0.16 to 101.8 ± 0.26%. 
All  formulations  were  acceptable  with  regard  to 
domperidone content.  
Moisture content and moisture absorption studies   
The  results  for  moisture  content  and  moisture 
absorption studies are shown in figure 2. The moisture 
content in the patches ranged from 2.02 ± 0.98 % 
(F1) to 4.45 ± 0.76 (F9).The moisture content in the 
formulations was found to be increased by increase in 
the concentration of HPMC. The moisture absorption 
in the formulations ranged from 1.27 ± 0.35 % (F1) 
to 4.16 ± 1.32% (F9). The moisture absorption was 
found to be higher in formulations F7, F8 and F9; 
which might be due to higher HPMC content. The 
lower  moisture  content  in  the  formulations  helps 
them to remain stable and becoming a completely 
dried and brittle film. Again, low moisture uptake 
protects the material from microbial contamination 
and bulkiness (25).  
WVTR Study  
The results of WVTR of patches are shown in table 
2.  The WVTR ranged from 3.42 x 10-3 to 6.81 x 10-3 
gm/cm2. Formulation F9 showed maximum water 
permeation, which might be due to higher content of 
HPMC and allowed more WVT through the patches 
than other patches. The order of WVT were F9 > F4 
> F3 > F2 > F5 > F8 > F7 > F1> F6. 
Mechanical Properties
The  tensile  testing  shows  the  film’s  strength  and 
elasticity,  as  it  was  evident  by  the  parameters  of 
tensile  strength  (TS),  elastic  modulus  (EM),  and 
elongation at break (E/B). A soft and weak polymer is 
characterized by a low TS, EM, and E/B; a hard and 
brittle polymer is defined by a moderate TS, high EM 
and low E/B; a soft and tough polymer is characterized 
by a moderate TS, low EM and high E/B; whereas 
a hard and tough polymer is characterized by a high 
TS, EM, and E/B (26). Another parameter which 
has been used as an indicator of the film’s overall 
mechanical quality is strain (27). A high strain value 
indicates that the film is strong and elastic. Hence, it 
is suggested that a suitable transdermal film should 
have a relatively high TS, E/B, and strain but a low 
EM. The results of mechanical properties (TS, E/B, 
EM and strain) are shown in table 3. The optimized 
formulation F6 exhibited TS and EM values (4.34 ± 
0.16 kg/mm2 and 10.74 ± 0.46 kg/mm2) respectively, 
which were significantly (P < 0.05) different from 
those of other formulations. These results revealed 
Formulation Tensile strength (Kg/mm2) Elongation at break (% mm-2) Elastic modulus (Kg/mm2) Strain
F1 2.04 ± 0.12 7.89 ± 2.10 5.25 ± 1.54 0.38 ± 0.04
F2 2.12 ± 0.13 9.58 ± 2.42 6.42 ± 1.94 0.33 ± 0.03
F3 2.23 ± 0.11 8.86 ± 2.34 6.59 ± 1.44 0.34 ± 0.05
F4 2.27 ± 0.15 11.5 ± 1.98 8.75 ± 1.36 0.26 ± 0.08
F5 2.90 ± 0.13 12.5 ± 1.56 9.44 ± 0.98 0.30 ± 0.06
F6 4.34 ± 0.16 14.6 ± 1.82 10.7 ± 0.46 0.40 ± 0.04
F7 4.50 ± 0.09 15.2 ± 1.57 11.2 ± 0.27 0.40 ± 0.05
F8 4.65 ± 0.11 16.3 ± 1.84 11.2 ± 0.14 0.41 ± 0.09
F9 4.85 ± 0.12 17.8 ± 1.93 12.3 ± 0.23 0.39 ± 0.08
Table 3. Tensile strength, Elongation at break, Elastic modulus, Strain of DOM transdermal patches
Values represent Mean ± SD (n = 3).
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that as the concentration of HPMC increased, the TS 
and EM also increased but E/B values decreased. An 
inverse relation was observed between TS and E/B. 
These observations indicate that formulation F6 was 
strong, but not brittle, and flexible.
In vitro release studies 
The drug release profiles of DOM from transdermal 
patches are represented in figure 3 and table 4. 
From the results and plots it is clear that the drug 
release  was  governed  by  polymer  content  and 
permeation enhancer content. An increase in the 
polymer  content  was  associated  with  decrease 
in  drug  release  rates.  Formulation  F6  exhibited 
maximum (90.7 %), and formulation F8 showed 
the minimum percent of drug release (40.2 %) in 
24 hrs. The order of drug release was found to be 
F8 < F7 < F9 < F5 < F4 < F2 < F1< F3< F6. The 
description  of  drug  release  profiles  by  a  model 
function  has  been  attempted  using  zero  order 
and  first  order  release  pattern  using  Korsmeyer 
equation (7).
                         Mt/Mα = K.tn                        (7)
Where Mt/Mα is the fractional release of drug, 
Mt is the amount which is released at time t, Mα 
is the total amount of drug which was present in 
the patches, t is the release time, K is the kinetic 
constant and n is the release exponent indicative 
of the operating release mechanism. The in vitro 
release  data  of  all  formulations  fitted  well  into 
the  Zero  order  equation,  correlation  coefficient 
values were between 0.925 and 0.996. The release 
Figure 2. Moisture content and moisture absorption of domperidone 
bilayered transdermal patches.
Figure 3. Cumulative percentage of drug release profiles from 
DOM transdermal patches.
Code Q24
a Release (mg) Q24
b Permeation (µg cm-2) Fluxc (µg cm-2 h-1) Kpd (cm h-1 × 10-2) LTe  (h)
F 1 7.82 ± 1.11 4785.6 ± 12.5 64.5 ± 0.27 0.64 ± 0.007 0.25 ± 0.005
F 2 6.11 ± 1.10 3758.5 ± 41.2 45.8 ± 0.24 0.45 ± 0.015 1.20 ± 0.014
F 3 8.18 ± 2.35 4399.6 ± 40.6 54.2 ± 1.32 0.54 ± 0.027 1.14 ± 0.241
F 4 7.82 ± 1.05 3650.2 ± 38.7 44.6 ±  0.28 0.44 ±  0.046 0.85 ± 0.093
F 5 6.18 ± 0.85 5846.2 ± 23.1 70.4 ± 1.87 0.70 ± 0.015 0.69 ± 0.068
F 6 9.07 ± 0.90 6806.6 ± 51.2 86.2 ± 1.85 0.86 ± 0.056 0.94 ± 0.032
F 7 5.11 ± 2.15 2713.0 ± 52.5 32.6 ± 2.13 0.32 ± 0.039 1.70 ± 0.007
F 8 4.02 ± 1.18 4018.1 ± 43.2 49.3 ± 0.19 0.49 ± 0.005 0.26 ± 0.104
F 9 5.71  ± 1.34 2978.1 ± 39.5 36.9 ± 0.5 0.36 ± 0.041 1.50 ± 0.216
Table 4. In vitro Release, Ex vivo Skin Permeation, Flux, Permeability Coefficient and Lag time of DOM bilayered transdermal patches.
a Cumulative amount of  drug  released; Mean ± SD (n= 3).
b Cumulative amount (µg) of drug permeated; Mean ± SD (n= 3).
cFlux; Mean ± SD (n= 3).
d Kp, Permeability coefficient; Mean ± SD (n= 3).
e LT, Lag time; Mean ± SD (n= 3).
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Figure 2: Moisture content and moisture absorption of domperidone bilayered transdermal 
patches
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Figure 3: Cumulative percentage of drug release profiles from DOM transdermal patches 
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pattern was found to follow anomalous transport 
mechanism,  as  it  was  evident  from  the  release 
exponent (n) which was found to be in the range 
of 0.32 to 0.73.
Ex vivo permeation studies  
The  results  of  ex  vivo  skin  permeation  of  DOM 
from  patches  are  shown  in  figure  4  and  table  4. 
The  formulation  F6  exhibited  maximum  amount 
(6806.64 µg) of drug permeated in 24 hrs with a flux 
of 86.02 µg/ h/cm (with a permeation coefficient of 
0.86 × 10-2 cm/h). Plotting the cumulative amounts 
of  drug  permeated  per  square  centimeter  of  the 
patches  through  the  rat  abdominal  skin  against 
time showed that, the permeation profiles of drug 
might follow zero order kinetics as it was evident 
by correlation coefficients 0.960 to 0.996, better fit 
than first order (r2 = 0.603 to 0.775) and Higuchi model 
(r2 = 0.865 to 0.958). The required flux for DOM 
was  approximately  88.28  µg/cm2/hr  and  was 
obtained by formulation F6 (86.02 ± 1.85 µg/cm2/hr). 
In order to reach the required flux, the patch area 
has to be increased upto 3.79 cm2. The results of 
drug permeation from transdermal patches of DOM 
through the rat abdominal skin confirmed that DOM 
was released from the formulation and permeated   
through  the  rat  skin  and  hence  could  possibly 
permeate through the human skin.
Drug-polymer interaction study    
DSC analysis of domperidone, HPMC, and physical 
mixture are shown in figure 5. DOM exhibited a 
sharp  endothermic  event  as  a  melting  peak  with 
the onset temperature of 234.6 oC (ΔH=138.9 J/g). 
The thermal behavior of HPMC exhibited no such 
phenomenon  in  any  temperature  intervals.  The 
appearance of a peak corresponding to the melting 
of DOM was also evident in the thermogram of the 
physical mixture. The results revealed a negligible 
change in the melting point of domperidone in the 
presence  of  polymeric  materials.  FTIR  spectra  of 
DOM (Figure 6) exhibited principal peaks at 3025.06 
cm-1  (N-H  stretching),  2818.07cm-1  (asymmetric 
C-H stretching), 1715.31 cm-1, 1694.22 cm-1 (C=O 
stretching), and 1489.15 cm-1 (N=C stretching peak). 
There were some other characteristic peaks which 
were  observed  at  1489.15  cm-1,  1147.18  cm-1and 
1062.18 cm-1. The FTIR spectrum of HPMC presented 
a profile without distinctly high peaks. The physical 
mixture showed approximate superimposition of the 
drug and HPMC. Both the DSC and FTIR results 
suggest that there was no interaction between drug 
and polymer which were used in the present study.
Stability study  
The stability of the optimized formulation (F6) was 
investigated as per ICH guidelines. The formulation 
was stored at a temperature 40 ± 0.5 oC and 75 ± 5% 
RH for 6 months. There was no significant change in 
Figure 4. Cumulative amount of domperidone permeated from 
transdermal patches through rat abdominal skin.
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Figure 4: Cumulative amount of domperidone permeated from transdermal patches through rat 
abdominal skin  
          
            
Figure 5: DSC thermograms of DOM (a), HPMC E15 (b), Physical mixture (c).  
Figure  5.  DSC  thermograms  of  DOM  (a),  HPMC  E15  (b), 
Physical mixture (c).
Figure 6. FTIR Spectra of DOM (a), HPMC E15 (b), Physical 
mixture (c).
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release and drug content. Only a 3.19% of degradation 
(lesser than initial drug content) was observed. As 
the degradation of the formulation is less than 5%, a 
shelf life of 2 years may be expected.
CONCLUSIONS  
Based on the results of the present study, it may be 
concluded that selected polymers were better suited 
for development of bilayered matrix type transdermal 
patches  of  DOM.  The  formulation  F6  showed   
maximum release and flux (86.02 µg/cm2/hr) which is 
closely related to the target flux (88.28 µg/cm2/hr). In 
order to reach the target flux, the patch area has to be 
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increased to 3.79 cm2. Further work is recommended to 
support its efficacy claims by long term pharmacokinetic 
and pharmacodynamic studies on human beings.
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